It bears repeating that I am quite the fan of inexpensive, readily available therapies to help save the lives of our patients. When I received this article from Caroline Welch, Pharm D. I was excited because I was hoping it would be a positive study. Unfortunately, it did not pan out and based on these data, atorvastatin does not seem to help out our critically ill patients with COVID-19. I know some people claim that we haven’t tried hard enough to repurpose current therapeutics with known toxicities and effects during this pandemic, and there may be some merit to that, but this is a case where these authors in Iran tried to do exactly that.
What dose of atorvastatin was used for their COVID ICU patients?
They used 20mg daily. Could they have used more? Definitely. But then you run increased risks of hepatotoxicity and elevations in the CK of these patients. They did the best they could in my opinion. As an aside, though, they weren’t getting only atorvastatin. >90% were receiving corticosteroids and >80% were receiving antivirals.
What were the Primary and Secondary Outcomes?
Here is a composite outcome of acute venous thrombosis, arterial thrombosis, treatment with ECMO, or all cause mortality. I am not a fan of these types of composite outcomes, to be honest. Seems like answering a lot of questions at the same time. There were no differences in the secondary outcomes either which included all-cause mortality, venous thromboembolism, and ventilator-free days. I recommend looking at table 1 which shows the baseline characteristics of the patients.
Should we start giving atorvastatin to our COVID patients in the ICU?
Nope. Nothing to do until further notice. If you’re looking for a therapy that does work in ICU patients, try baricitinib. I know that looking at figure 3 which shows the subgroup analysis could be encouraging. After all, it shows odds ratios that lean towards atorvastatin being beneficial in COVID ICU patients. But these are not statistically significant. In a study with almost 500 ICU patients, the claim of it being underpowered is not valid here, in my opinion, in order to find a treatment effect. They did a great job. If the patient was already on a statin, continue it. If not, don’t start it to potentially improve their COVID outcome.
Citation
INSPIRATION-S Investigators. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ. 2022 Jan 7;376:e068407. doi: 10.1136/bmj-2021-068407. PMID: 34996756.
Link to Article
Link to FULL FREE PDF
How to Support My Work
My efforts are at no cost to you and I would like to keep it that way. You have to look at ads on this website, listen to them on my podcast and YouTube content. Thanks for bearing with me. You could also support my work by clicking on my Amazon Affiliate links prior to ordering things off of Amazon.
For example, if you want to learn more about Mechanical Ventilation, I recommend starting off with The Ventilator Book by Will Owens. If you click on that link, a window for Amazon will open up and I will earn between a 1-3% commission at no expense to you. The fun thing is that if you order anything else on Amazon, I will earn that amount off of your shopping cart even if you do not purchase the book. Pretty cool, right? In 2020, Amazon Affiliates helped me pay for the hosting of my website, LLC fees, and Netflix.
Although great care has been taken to ensure that the information in this post is accurate, eddyjoe, LLC shall not be held responsible or in any way liable for the continued accuracy of the information, or for any errors, omissions or inaccuracies, or for any consequences arising therefrom.
